Nevoid Basal Cell Carcinoma Syndrome - 25 Studies Found
Withdrawn |
: Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) : Basal Cell Carcinoma : 2010-07-06 :
|
Completed |
: Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face : Neoplastic Syndrome : 2007-06-20 : Drug: tazarotene Tazarotene is a member of the acetylenic class of retinoids. |
Completed |
: Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants :
: 2007-02-08 :
|
Completed |
: Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome : Non-melanomatous Skin Cancer : 2001-09-13 : Drug: celecoxib |
Completed |
: Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients :
|
Recruiting |
: Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas : Basal Cell Carcinoma : 2015-12-14 : Drug: Vismodegib Vismodegib 150 mgs po qd for 3 months |
Active, not recruiting |
: A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas : Basal Cell Carcinoma : 2013-03-19 :
|
Recruiting |
: Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) : Basal Cell Carcinoma in Basal Cell Nevus Syndrome : 2015-01-21 : Drug: SUBA-Itraconazole Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily. |
Completed |
: The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases :
|
Active, not recruiting |
: Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma :
|